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Diabetes is associated with increased risk of fracture, although type 2 diabetes is character-
ized by normal bone mineral density (BMD). The fracture risk of type 1 diabetes increases
beyond an explained by a decrease of BMD. Thus, diabetes may be associated with a
reduction of bone strength that is not reflected in the measurement of BMD. Based on
the present definition, both bone density and quality, which encompass the structural and
material properties of bone, are important factors in the determination of bone strength.
Diabetes reduces bone quality rather than BMD. Collagen cross-linking plays an important
role in bone strength. Collagen cross-links can be divided into lysyl hydroxylase and lysyl
oxidase-mediated enzymatic immature divalent cross-links, mature trivalent cross-links,
and glycation- or oxidation-induced non-enzymatic cross-links (Advanced Glycation End-
products: AGEs) such as pentosidine. These types of cross-links differ in the mechanism
of formation and in function. Not only hyperglycemia, but also oxidative stress induces
the reduction in enzymatic beneficial cross-links and the accumulation of disadvantageous
AGEs in bone. In this review, we describe the mechanism of low bone quality in diabetes.
Keywords: collagen cross-links, advanced glycation end products, pentosidine, osteoporosis, diabetes, bone quality
Diabetes itself is associated with increased risk of fracture (Vester-
gaard, 2007), although type 2 diabetes is often characterized by
normal or high bone mineral density (BMD). Thus, diabetes may
be associated with a reduction of bone strength that is not reflected
in the measurement of BMD.
According to the recent definition of bone strength, BMD,
and quality in terms of tissue material properties are important
determinants. Bone matrix consists of a two-phase composite
material in which the mineral phase provides stiffness and colla-
gen fibers provide tensile strength, ductility, and toughness. Bone
tissue material properties are regulated by bone tissue turnover
rate, cellular activity, and the levels of oxidative stress and glyca-
tion (Seeman and Delmas, 2006). Collagen enzymatic and non-
enzymatic cross-link formation in bone affect directly not only the
mineralization process, but also bone strength. Impaired enzy-
matic cross-linking and/or an increase in non-enzymatic cross-
links, pentosidine (Pen), which is surrogate marker of advanced
glycation end products (AGEs), in bone collagen have been pro-
posed as a major cause of bone fragility in aging, osteoporosis,
and diabetes mellitus (Robins and Bailey, 1977; Knott and Bailey,
1998; Satio and Marumo, 2010). This review will summarize the
mechanism of formation of cross-linking in bone collagen and
important aspects of alterations in collagen cross-link formation,
in diabetes.
CROSS-LINK FORMATION IN BONE COLLAGEN
Type I collagen is the most abundant protein component in bone
matrix. Type I collagen consists of two non-helical regions called
telopeptides at the amino-terminal (N) and carboxyl-terminal (C)
and a central triple helical region. Collagenous plays important
roles in tissue mechanical strength and this is attributed to the
formation of intermolecular cross-linking formation between the
adjacent collagen molecules.
Stabilization of newly formed collagen fibers is initially
achieved by the formation of covalent cross-links between neigh-
boring collagen molecules. Collagen cross-links can be divided
into two types. One is lysyl oxidase (LOX)-mediated cross-linking
(enzymatic cross-links) and glycation or oxidation-induced AGEs
cross-linking. These two types vary in the mechanism of formation
and display functional differences.
ENZYMATIC CROSS-LINKS OF COLLAGEN
Enzymatic cross-link formation in bone collagen is regulated
by the action of two types of enzymes: the lysine hydroxylases
(Procollagen-lysine, 2-oxyglutarate, 5-dioxigenase, PLOD, LH)
and LOX. Lysine hydroxylases regulate tissue specific enzymatic
cross-link patterns intracellularly (Robins and Bailey, 1977; Bank
et al., 1999; Uzawa et al., 1999; Saito et al., 2004a). After intracel-
lular determination of the degree of hydroxylation of lysine (Lys),
collagen molecules are secreted into the extracellular space. LOX
only acts on extracellular collagen fibers and binds to specific Lys
or hydroxylysine (Hyl) residues in the telopeptides to control total
amount of enzymatic cross-linking (Figure 1).
The first step of cross-link formation extracellularly is conver-
sion ofε-amino groups of specific for cross-linking site such as Lys
and Hyl residues located in the telopeptide domains into the mol-
ecule aldehyde to give allysine and hydroxyallysine, respectively
(Figure 1). This reaction occurs via the action of LOX follow-
ing extracellular aggregation of collagen molecules into fibers
(Eyre et al., 1984). An excessive formation of enzymatic cross-
links does not occur in the physiological mineralization process
in vivo (Eyre et al., 1988; Yamauchi and Katz, 1993; Saito et al.,
1997) and in vitro (Kuboki et al., 1992; Uzawa et al., 1999; Saito
et al., 2003, 2004a) because the total amount of enzymatic cross-
linking in bone is strictly regulated by the expression of LOX.
Four LOX like-proteins (LOXL1-4) have been identified although
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FIGURE 1 |The pathway of collagen crosslink formation Lysine
hydroxylase and lysyl oxidase regulate reaction is the
first step or enzymatic cross-linking. The first step for AGEs
formation is the non-enzymatic glycation, oxidation, or glycoxidation
between the helical Lys or Hyl residue and sugar. de-H-DHLNL:
dehydro-dihydroxylysinonorleucine, de-H-HLNL: dehydro-
hydroxylysinonorleucine, de-H-LNL: dehydro-lysinonorleucine, CML:
carboxyl methyl lysine.
their function and tissue specificity remain unclear (Atsawasuwan
et al., 2005). Pyridoxal phosphate (vitamin B6) acts as an essen-
tial co-factor of LOX (Bird and Levene, 1982; Wang et al., 1996).
We showed that vitamin B6 deficiency in rats resulted in a 25%
reduction in LOX mediated cross-link formation in bone com-
pared to regularly fed rats (Fujii et al., 1979). The other positive
regulatory factors of LOX are reported. Various growth factors
acting in bone formation such as transforming growth factor beta
(TGF-β) (Feres-Filho et al., 1995), connective tissue growth fac-
tor (CTGF) (Hong et al., 1999), and insulin-like growth factor I
(IGF-I) (Reiser et al., 1996). Estrogen is also important regulatory
factor of LOX expression. Ovariectomy in mouse led to decrease
the activity of LOX down to 25% after OVX, but this reduced
activity was completely rescued by estradiol injection (Ozasa et al.,
1981). Furthermore, aging-related reduction in estrogen correlates
to the activity of LOX in bone (Sanada et al., 1978). In contrast,
the negative regulatory factors of LOX are reported. Fibroblast
growth factor (FGF) (Feres-Filho et al., 1996), prostaglandin E2
(Saito et al., 2004b), and tumor necrosis factor-alpha (TNF-alpha)
(Rodríguez et al., 2008) suppresses LOX gene expression and enzy-
matic activity. In terms of osteoblastic activity, deficient enzymatic
crosslink formation by beta-aminopropionitrile (BAPN) treat-
ment hampers osteoblastic differentiation (Turecek et al., 2008).
These results indicate that proper enzymatic cross-link formation
is essential for osteoblastic differentiation. Homocysteine (Hcys)
thought to interfere with enzymatic cross-link formation via a
reduction in gene expression and enzymatic activity of LOX (Liu
et al., 1997; Raposo et al., 2004). Hcys binds competitively to the
aldehydic groups of precursor of cross-linking sites and results
in a marked decrease in cross-linking (Kang and Trelstad, 1973).
Recently, mildly elevated plasma homocysteine in the general pop-
ulation was reported to be a independent fracture risk (Yang et al.,
2012). This plausible mechanism is thought to reduce bone quality
in terms of abnormal collagen cross-link formation (Saito et al.,
2006a; Blouin et al., 2009). Hyperhomocysteinemia is a risk fac-
tor of arteriosclerosis as well as fracture risk in general population
(McLean and Hannan, 2007). Type 2 diabetes also increases plasma
level of homocysteine, resulting in arteriosclerosis (Ebesunun and
Obajobi, 2012). Thus, hyperhomocysteinemia in diabetes may
show an additive adverse effect of bone quality. The precursor
of enzymatic cross-linking amino-acids such as the telopeptide
Lys aldehydes (allysine) and Hyl aldehydes (hydroxyallysine) in
the N-terminal telopeptide and in the C-terminal telopeptide
then react and condensate with Lys or Hyl residues in the triple
helical region of an adjacent collagen molecule to form diva-
lent immature cross-links called deH-dihydroxylysinonorleucine
(DHLNL), deH-hydroxylysinonorleucine (HLNL), and deH-
lysinonorleucine (LNL). The divalent cross-links undergo a spon-
taneous reaction with another telopeptide Lys or Hyl alde-
hyde to form trivalent mature pyridinium or pyrrole cross-links
(Figure 1). The presence of mature cross-links was first suspected
when the amount of immature divalent cross-links markedly
decreased with advancing age in human bone (Fujii et al., 1976),
Mature cross-links are pyridinium cross-links such as pyridinoline
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(PYD) and deoxypyridinoline (DPD) are formed via the hydrox-
yallysine pathway. Pyrrole cross-links, such as (pyrrolidine) PYL
and deoxy-pyrrolidine (DPL) are also characterized as mature
trivalent cross-links (Brady and Robins, 2001; Banse et al., 2002).
The proposed mechanism of pyrrole cross-link formation is by
condensation of de-HLNL/de-DHLNL reacting with another ally-
sine (Kuypers et al., 1992), or by interaction of two divalent
immature cross-links including deH-HLNL (Hanson and Eyre,
1996).
ADVANCED GLYCATION END PRODUCTS (AGEs,
NON-ENZYMATIC CROSS-LINKS)
Although enzymatic cross-links have the beneficial effects on
bone strength, non-enzymatic AGEs cross-linking within colla-
gen fibers deteriorates the biological and mechanical functions of
bone (Vashishth, 2007). Pen is well-established as an intermolec-
ular cross-linking type of AGEs in bone (Saito et al., 1997, 2006b,
2008, 2010a, 2011a; Wang et al., 2002; Viguet-Carrin et al., 2008)
(Figure 1). While the content of Pen in bone correlates posi-
tively to total amount of fluorescent AGEs, the measurement of
pen used as a surrogate marker of total AGEs formation (Dong
et al., 2011). There is no direct evidence whether other AGEs
cross-links, such as vesperlysine (Nakamura et al., 1997) identi-
fied from AGEs-induced bovine serum albumin, non-fluorescent
component-1 (NFC-1) identified from aorta (Sims et al., 1996),
and glucosepane (Sell et al., 2005) are formed in bone collagen.
Although Pen is just one of many AGEs in bone, Pen measure-
ment in bone is a common quantification method as Pen can be
easily and precisely quantified in small specimens by HPLC (Bank
et al., 1997; Saito et al., 1997; Viguet-Carrin et al., 2009). This sug-
gests that the pathway of their formation may be similar and Pen
may be a useful marker of whole AGEs in bone.
The first step of AGEs cross-link formation of collagen is
that the aldehyde of an open chain form of glucose, ketose,
or other metabolic intermediate (glyoxal, methylglyoxal, and 3-
deoxyglucosone) reacts with a freeε-amino group of collagen-
bound Lys or Hyl to form a glycosyl-Lys via Schiff base formation
(Robins and Bailey, 1972). The hexosyl Lys or Hyl is stabilized by
spontaneous Amadori rearrangement (Figure 1). The Amadori
adduct reaction with amino-acids such as Lys or arginine (Arg)
in adjacent collagen molecules to form AGEs cross-links between
collagen molecules (Monnier et al., 2008). AGEs are formed spon-
taneously by non-enzymatic glycation or oxidation. AGEs cross-
links such as Pen are likely to be formed between helical Lys and
Arg without involvement of the telopeptides. It is well-established
that increasing inter-helical cross-links such as Pen may contribute
to tissue stiffness and resistance to breakdown of the non-helical
telopeptides by pepsin (Brennan, 1989; Satio, 1999).
Non-cross-linking types of AGEs such as carboxymethyllysine
(CML) as well as cross-linking type of AGEs deteriorate osteoblas-
tic function (Mercer et al., 2007; Ogawa et al., 2007) via the
interaction with the cell surface receptor of AGEs, RAGE (Cortizo
et al., 2003; Cui et al., 2011; Li et al., 2012). Similar disadvantageous
effect of Pen on osteoblastic function is also reported (Sanguineti
et al., 2008). In contrast, the effects of AGEs on bone resorption
by osteoclast remain controversial. A non-histone nuclear pro-
tein, high-mobility group box 1 (HMGB1) is released from bone
marrow macrophages in response to, RANKL stimulation. The
extracellular HMGB1, through RAGE, in large, regulates osteo-
clastic actin cytoskeleton remodeling, differentiation, and function
(Zhou et al., 2008). Thus, AGEs may increase osteoclast activity
(Miyata et al., 1997). The results from in vitro study are consistent
with other evidence that an increasing of AGEs formation occurs
in bone from patients with post-menopausal osteoporosis (Saito
et al., 2006a,b) and chronic renal failure (Mitome et al., 2011) with
high turnover bone. An opposite conclusion compared to Miy-
ata’s results in an in vitro study using rabbit and human mature
osteoclasts was reported (Miyata et al., 1997). In contrast, Valcourt
et al. (2007) new showed an opposite effect of AGEs on osteoclast
activity than Miyata’s study (Miyata et al., 1997). This result seems
to explain the increase in Pen formation in bone from type 1 and
2 diabetic animal models (Saito et al., 2006c; Silva et al., 2009) and
the patients with type 2 diabetes (Okazaki et al., 1997) with low
bone turnover. AGEs formation is regulated by glycemic control,
tissue life span, and oxidative stress (Saito et al., 2006a,c, 2010a).
The formation of AGEs inhibits competitively enzymatic cross-
link formation because AGEs are formed between Lys residues,
which are essential sites of enzymatic cross-linking in collagen
molecules.
Advanced glycation end products cross-links themselves reduce
bone strength without cellular dysfunction. An excessive forma-
tion of AGEs cross-links in bone makes collagen fibers brittle,
thereby leading to the accumulation of microdamage, which
results in deterioration of post-yield properties and toughness
(Saito et al., 2008). Induction of AGEs in bovine (Vashishth et al.,
2001; Garnero et al., 2006) and human (Tang et al., 2007) bone col-
lagen by ribosylation in vitro resulted in a decrease in post-yield
strain and energy. Induction of AGEs cross-links in bovine bone
collagen by ribosylation for 38 days in vitro decreased post-yield
strain and energy (Vashishth et al., 2001). A similar result using
human cancelous bone incubated with ribose for 7 days (Tang
et al., 2007). Garnero et al. (2006) also demonstrated that incuba-
tion of fetal bone specimens for 60 days at 37 °C induced a more
than 50-fold increase of Pen. In this study, an independent con-
tribution of Pen to bone strength was determined by multivariate
regression analyses. Interestingly, an increase in Pen in an incu-
bation time-dependent manner in fetal bone correlated positively
to post-yield energy absorption. In this case, Pen accumulation
showed a positive effect on bone strength. To explain the reason
for these contradictory results, we must consider differences in the
level of Pen in bone between fetal bovine bone and elderly human
bone. After incubation, the content of Pen in fetal bovine bone
did not reach the levels of bone from the elderly people, but more
closely matched levels found in young adults (Saito et al., 1997).
Thus, the relationships observed in Garnero’s study (Garnero et al.,
2006) might represent a correlation between fetal and young bones
rather than between adult and elderly. Recently, the content of Pen
correlates positively and significantly to total AGEs in bone (Karim
et al., 2013). Although Pen is a minor type of AGEs in bone col-
lagen, the estimation of Pen in bone is good surrogate marker
of whole AGEs in bone. Because these in vitro incubation stud-
ies exclude the effect of AGEs on cellular activities and maintain
constant bone architecture and BMD, AGEs cross-linking itself
may deteriorate bone mechanical strength at a material level. Such
www.frontiersin.org June 2013 | Volume 4 | Article 72 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Saito and Marumo Bone quality in diabetes
disadvantageous effects on bone mechanical properties induced
by the excessive accumulation of AGEs cross-links in bone have
been shown to correlate with deformation and damage of bone
(Wang and Qian, 2006) and microdamage accumulation (Saito
et al., 2008). Unfortunately, these studies that investigate the cor-
relation between bone strength and collagen cross-links are limited
to acquiring information of AGEs cross-links without accounting
for the presence of immature divalent and mature trivalent enzy-
matic cross-links. Some studies perform only evaluation of AGEs.
Thus, we analyzed the correlation between beneficial enzymatic
cross-links, disadvantageous AGEs cross-linking Pen, and bone
strength by using low bone quality diabetic animal model (Table 1)
(Saito et al., 2006c). There was significant association between the
enzymatic cross-links and mechanical properties of bone in the
WBN/Kob rats. The extent of total enzymatic cross-linking associ-
ated modest with stiffness and elastic modulus, but no association
with energy absorption and maximum load. In contrast, the con-
tent of Pen and the ratio of Pen to total enzymatic cross-links had
significant association with not only stiffness and elastic modulus
but also energy absorption and maximum load. Interestingly, the
ratio of Pen to total enzymatic cross-links was more consistent with
bone mechanical properties than with total enzymatic cross-links
or Pen. These results indicates that the simultaneously estimation
of the immature divalent and mature trivalent enzymatic and non-
enzymatic AGEs cross-link is important to understand the role of
collagen crosslink formation on bone strength.
ENZYMATIC AND AGEs CROSS-LINKS IN DIABETES
MELLITUS
Although type 2 diabetes is characterized by normal or high BMD,
diabetes is associated with an increased risk of fracture (Vester-
gaard, 2007; Yamamoto et al., 2008, 2009a,b; Schwartz et al., 2011;
Table 1 | Association between collagen cross-link parameters and
bone mechanical properties in the prediabetic and diabetic WBN/Kob
rats.
Energy
absorption
Stiffness Elastic
modulus
Maximum
load
Total enzymatic
cross-links
0.229 0.557c 0.521c 0.285
Pentosidine 0.312a 0.677c 0.579c 0.448b
Pentosidine/total
enzymatic cross-links
0.332a 0.699c 0.603c 0.460b
The values show the correlation coefficients between bone mechanical proper-
ties and cross-link parameters such as total enzymatic cross-links and Pentosi-
dine (expressed in mol or mmol/mol of collagen) in the prediabetic and diabetic
WBN/Kob rats (6–18 months of age).
The value of total enzymatic cross-links is sum of immature (DHLNL, HLNL, LNL)
and mature (Pyr, Dpyr) cross-links.
The value of Pentosidine/total enzymatic cross-links is the ratio of the content of
Pentosidine to the content of total enzymatic cross-links.
Asterisks (a, b, c) indicate p values at p<0.05, p<0.01, and p< 0.0001, respec-
tively.
Saito et al. (2006c) with permission.
Leslie et al., 2012). Vestergaard reported (Vestergaard, 2007) that
the fracture risk in type 1 diabetes increased significantly much
more pronounced than what could be explained from a reduction
in BMD. Thus, both type 1 and 2 diabetes may be associated with a
reduction of bone strength that does not necessarily reflect BMD.
Therefore, it is thought that diabetes deteriorates “bone quality”
rather than bone mass and BMD, which suggests impaired mater-
ial properties in terms of collagen cross-link formation. However,
little is known for collagen enzymatic and AGEs cross-links abnor-
malities in diabetes. Because the metabolism of bone collagen in
diabetic patients is influenced by many factors including age of
onset, disease duration, insulin status, and glycemic control, we
should analyze a suitable animal model for type 1 and type 2
diabetes that is closest to the human disease in terms of bone
properties (Okazaki et al., 1997; Silva et al., 2009).
In terms of type 2 diabetes, we demonstrated that impaired
enzymatic cross-links and an excessive formation of AGEs cross-
linking Pen in bone collagen decreased bone strength with-
out alteration of collagen content and BMD in spontaneously
WBN/Kob rats (Figure 2) (Saito et al., 2006c). In this study, a
significant reduction in enzymatic cross-linking even in the sub-
clinical diabetes stage that resulted in a significant decrease in
bone strength without changing BMD and AGEs cross-linking
(Figure 2). The cause of an impaired enzymatic cross-links in the
pre-clinical diabetic stage may be due to a vitamin B6 deficiency,
which is essential for the action of LOX (Bird and Levene, 1982).
Serum levels of vitamin B6 such as pyridoxal (PL) and pyridox-
amine (PM) in the WBN/Kob rats decreased after 6 months of age
with age and the serum levels of PL and PM in the WBN/Kob
rats were significantly lower than those in the age-matched Wis-
tar rats after 6 months of age. The content of total enzymatic
cross-linking associated strongly with serum PL level, whereas
the content of Pen had modest association with not only blood
glucose but also serum PL and PM levels. It is well known that
vitamin B6 are consumed when upregulation of gluconeogenesis
takes place in both subclinical and clinical diabetic stages, a latent
deficiency of vitamin B6 may provoke impaired LOX-controlled
enzymatic cross-linking. We previously reported vitamin B6 defi-
ciency in normal rats reduced enzymatic cross-link formation in
bone compared to regularly fed rats (Fujii et al., 1979). An excess
of enzymatic cross-link formation cannot occur in vivo (Eyre et al.,
1988; Saito et al., 1997) and in vitro (Kuboki et al., 1992; Uzawa
et al., 1999; Saito et al., 2004a) because enzymatic cross-link for-
mation is strictly regulated by LOX activity. Therefore, enzymatic
cross-links in physiological conditions may be proportional to the
mechanical properties of collagen fibers within a beneficial range
without brittleness (Saito et al., 2006c, 2010b, 2011b,c). Therefore,
reduction of LOX activity by lathyrogens such as BAPN, pyridoxal
phosphate (vitamin B6) deficiency, or copper deficiency induces
not only impaired immature divalent cross-links, but also their
mature trivalent forms such as pyridinium and pyrrole cross-
links, resulting in a decrease of bone strength (Opsahl et al., 1982;
Oxlund et al., 1995). Thus, even in a pre-clinical diabetic stage,
bone material property is not necessary has sufficient strength.
After the onset of diabetes, there was a steady decrease in enzy-
matic cross-links and a significant increase in AGEs cross-link, Pen,
which was consistent with a significant reduction of bone strength
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FIGURE 2 | Serum glucose level (A) and bone mineral
density (B), collagen content in bone (C), maximum load (D),
total enzymatic cross-link content (the sum of immature
divalent and mature trivalent pyridinium crosslinks) (E), and
AGEs cross-link Pen content (F) in the non-diabetic Wistar rats
(closed circle) and the diabetic WBN/Kob rats (open circle).
*p<0.05, vs. the age-matched Wistar rats. (Saito et al. (2006c)
with permission).
compared to non-diabetic control rats in spite of a lack of change
in BMD (Figure 2). As described above, AGEs are thought to be
formed between sugar and Lys residues, essential sites of enzy-
matic cross-linking in collagen, resulting in competitive inhibition
of cross-link formation (Monnier et al., 2008). Thus, not only vita-
min B6 deficiency, but also accumulation of AGEs may deteriorate
enzymatic crosslink formation after the onset of diabetes. A trend
toward increased loss in bone quality in terms of impaired enzy-
matic cross-link formation and/or an excessive accumulation of
AGEs cross-links in type 1 and 2 diabetes may lead to accelerated
increase of bone fragility, which is independent of BMD.
In terms of type 1 diabetes, Tomasek et al. (1994) reported
that streptozotocin-induced type 1 diabetes exhibited an increase
in collagen-linked fluorescence (an indicator of AGEs) that was
coincident with reduced bone strength, BMD, and bone turnover
as estimated by serum levels of osteocalcin compared to control
rats. Silva et al. (2009) reported detailed information regarding
collagen cross-links, architecture of bone, and bone strength using
streptozotocin-induced type 1 diabetic rats. They showed that
type 1 diabetes caused trabecular bone loss, a reduction in dia-
physeal growth and a marked increase in AGEs cross-link, Pen,
without alteration in the content of enzymatic mature pyridinium
cross-links or collagen concentration in bone. An increase in AGEs
cross-link, Pen, modestly reduced material properties of bone from
type 1 diabetic rats.
The major non-collagenous bone matrix protein, osteocalcin,
is also important determinant of bone material properties (Tanaka
et al., 2011; Poundarik et al., 2012). The molecular deformation
and fracture mechanics models, illustrating the important role
of osteocalcin in dilatational band formation, and predict that the
nanometer scale of tissue organization, associated with dilatational
bands, affects fracture at higher scales, and determines fracture
toughness of bone (Poundarik et al., 2012).
The osteoporotic hip fracture cases without diabetes shows the
significant lower level of osteocalcin in bone compared to non-
fractured subjects despite hip osteoarthritis (Tanaka et al., 2011).
Interestingly, it is well known that the serum levels osteocalcin in
patient with diabetes is significantly lower than the subjects with-
out diabetes (Starup-Linde, 2013). Recently, the inverse correlation
between serum levels of sclerostin and osoteocalcin in diabetes was
reported despite animal model (Kim et al., 2013; Starup-Linde,
2013). Sclerostin is a Wnt-pathway antagonist produced in the
osteocytes (Gennari et al., 2012). The Wnt-pathway promotes
osteoblastogenesis and decreases osteoclastogenesis (Manolagas
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and Almeida, 2007). Since sclerostin is secreted by osteocytes,
osteocyte may be a candidate for central role to bone homeosta-
sis in diabetes. Furthermore, AGEs also reduces osteocalcin gene
expression in mouse stromal ST2 cells (Okazaki et al., 2012). Thus,
increased level of sclerostin as well as hyperglycemia, increased
oxidative stress, and AGEs in diabetes may decrease osteocalcin
production and accumulation.
To date, there is no suitable biomarker for estimation of bone
material properties. Because plasma and urine Pen levels are sig-
nificantly higher in diabetic patients compared with age-matched
healthy subjects (Takahashi et al., 1993; Sugiyama et al., 1998),
plasma or urinary levels of Pen may correlate with an independent
fracture risk in diabetic patients with low bone quality. Yamamoto
et al. (2008, 2009a) reported that a high level of serum Pen or low
level of the endogenous secretory receptor for AGEs (esRAGE)
acting as decoy receptor of AGEs was independent of prevalent
and incident fracture risk in elderly diabetic women. Schwartz et
al. (Yamauchi and Katz, 1993) reported that urinary Pen levels
were associated with incident clinical fracture or prevalent verte-
bral fracture, as well as bone turnover markers, in older adults with
diabetes in the Health Aging and Body Composition (Health ABC)
study. Thus, simultaneous estimation of BMD, bone turnover
markers, and a surrogate marker for AGEs, Pen, may be suitable
for estimation of fracture risk of diabetic patients.
CONCLUSION
Diabetes showing hyperglycemia, oxidative stress, and hyperho-
mocysteinemia deteriorates bone material properties in terms of
collagen post-translational modification such as enzymatic imma-
ture and mature cross-links and non-enzymatic AGEs formation.
Furthermore, the adverse effects of AGEs on bone cells via the
interaction to RAGEs on bone metabolism accelerate bone fragility
in diabetes. Proper collagen cross-link formation seems to directly
affect the physiological mineralization process and microdamage
accumulation. Enzymatic and AGEs cross-link formation are reg-
ulated by LOX activity, levels of glycation and oxidative stress, and
bone turnover. Future studies needed to elucidate what other reg-
ulatory factors of cross-link formation contribute to the process.
The recent literature regarding the roles of AGEs allows us to
hypothesize that AGEs could explain the molecular link between
primary osteoporosis and diabetes. If so, the agent for inhibiting
AGEs formation in bone such as raloxifene (Saito et al., 2010a),
teripartide (Saito et al., 2011a), and vitamin B6 (Satio et al., 2005)
may reduce fracture risk. The development of a non-invasive bio-
marker that reflects the actual amount of cross-links in matrix,
possibly a bone-specific marker, is needed to investigate individ-
ual differences in collagen cross-links and susceptibility to bone
fractures. Plasma and urinary levels of Pen may be candidates for
the estimation of low bone quality.
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